# Tshireletso: Safety, Efficacy and Feasibility of Cabotegravir-LA PrEP in a Breastfeeding Population in Botswana

> **NCT05986084** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Beth Israel Deaconess Medical Center** · enrollment: 500 (estimated)

## Conditions studied

- Pre-Exposure Prophylaxis (PrEP)
- Breast Feeding

## Interventions

- **DRUG:** Cabotegravir Injection [Apretude]

## Key facts

- **NCT ID:** NCT05986084
- **Lead sponsor:** Beth Israel Deaconess Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-11-30
- **Primary completion:** 2027-08-31
- **Final completion:** 2027-11-30
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2026-03-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05986084

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05986084, "Tshireletso: Safety, Efficacy and Feasibility of Cabotegravir-LA PrEP in a Breastfeeding Population in Botswana". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05986084. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*